Loading
companiesCompany
Massive Bio
Massive Bio uses artificial intelligence to read a cancer patient's medical records and match them to clinical trials they may be eligible for, anywhere in the world, with doctors checking the results.
Overview
Massive Bio, based in New York and co-founded by Selin Kurnaz, oncologist Arturo Loaiza-Bonilla and Cagatay Culcuoglu, runs the SYNERGY-AI platform, which analyses more than 500 clinical and molecular data elements from uploaded records to match patients to more than 19,000 active oncology and haematology trials, with physician review and a report within 24 hours. It reports more than 200,000 onboarded patients, 17 pharmaceutical customers and operations in 18 countries, and in November 2025 became the AI trial matching provider for the American Cancer Society's ACS ACTS clinical trial equity programme. In May 2020 Massive Bio raised USD 9 million led by Revo Capital and Kenan Turnacıoğlu with DEG participating; the release did not name the series, so it is not entered as a round. A later USD 2.6 million raise from strategic investors is undated on the company site.
Notes
top- The 2020 USD 9 million round and the USD 2.6 million follow-on have no series names in company releases, so they are described in the summary only. Founding year not sourced. Stage set to startup by default.
Similar pages
- CompanyTriNetX
Shares AI trial matching & clinical decision support, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
- IdeaSimulate eligibility against real-world data before every protocol is locked
Shares AI trial matching & clinical decision support, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
- IdeaTrial matching inside the electronic record at the moment a treatment is chosen
Shares AI trial matching & clinical decision support, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
- CompanyTrial Library
Shares AI trial matching & clinical decision support, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
- TechnologyMed-Gemini and MedLM (Google)
Shares AI trial matching & clinical decision support, AI in oncology roadmap: pattern readers → foundation models → agents in the workflow.
- CollectionFlatiron Health and Foundation Medicine Clinico-Genomic Database
Shares AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
- IdeaAI-assisted central imaging reads to cut endpoint cost and variability
Shares AI in oncology roadmap: pattern readers → foundation models → agents in the workflow, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
- IdeaA national platform trial that every ctDNA-positive patient can join
Shares AI trial matching & clinical decision support, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on.
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A trial matching service for patients and their doctors, combining an algorithm over the public registry with a human team that works the case.
Massive Biono source outside the company found